Author(s): Elza Lomaia, Nadiya Siordiya, Georgy Dimov, et. al. EHA Library. May 16, 2019; 268118; PB2207 Session topic: 16. Myeloproliferative neoplasms – Clinical Abstract: PB2207 Type: Publication Only Background: Ruxolitinib (RUXO) improves long-term prognosis in patients (pts) with primary or post-polycythemia/post-thrombocythemia myelofibrosis (MF). The most patients experience spleen response. Meanwhile there...
Pro zobrazení tohoto obsahu je třeba být přihlášen.